Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized treatment strategies for metabolic dysfunction-associated fatty liver disease in prediabetes
2021-000152-19Phase 3Active
- Sponsor
- Centro de Investigación Biomédica en Red
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of metformin and pioglitazone in metabolic dysfunction-associated steatotic liver disease (MASLD) and prediabetes (3 arms), sponsored by Centro de Investigación Biomédica en Red. Started Feb 2022; status: active.
02
Drugs
metforminpioglitazone
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)prediabetes
Beyond the preview
Go deeper on 2021-000152-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000152-19.